Nocebos in Daily Clinical Practice. The Potential Side Effects of the Treatment Context and the Patient-Doctor Interaction on Pain in Clinical Populations

Placebo and Pain: From Bench to Bedside

Volumn , Issue , 2013, Pages 257-266

  Doering, Bettina K ^a   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clinical population; Medical treatment; Nocebo; Pain; Side effects

Indexed keywords

EID: 84902422729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397928-5.00025-8     Document Type: Chapter

References (72)

1. Reeves R.R., Ladner M.E., Hart R.H., Burke R.S. Nocebo effects with antidepressant clinical drug trial placebos. Gen Hosp Psychiatr 2007, 29(3):275-277.
2. Colloca L., Miller F.G. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011, 73:598-603.
3. Rief W., Bingel U., Schedlowski M., Enck P. Mechanisms involved in placebo and noceco responses and implications for drug trials. Clin Pharm Ther 2011, 90:722-726.
4. Lorenz J., Hauck M., Paur R.C., et al. Cortical correlates of false expectations during pain intensity judgments-a possible manifestation of placebo/nocebo cognitions. Brain Behav Immun 2005, 19:283-295.
5. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006, 26:12014-12022.
6. Scott D.J., Stohler C.S., Egnatuk C.M., et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008, 65:220-231.
7. Rodriguez-Raecke R., Doganci B., Breimhorst M., et al. Insular cortex activity is associated with effects of negative expectation an nociceptive long-term habituation. J Neurosci 2010, 30:11363-11368.
8. Kong J., Gollub R.L., Polich G., et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008, 28:13354-13362.
9. Mitsikostas D.D., Mantonakis L.I., Chalarakis N.G. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011, 31:550-561.
10. Mitsikostas D.D., Chalarakis N.G., Mantonakis L.I., et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for clinical practice. Eur J Neurol 2012, 19:672-680.
11. Barsky A.J., Saintfort R., Rogers M.P., Borus J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002, 287:622-627.
12. Rief W., Avorn J., Barsky A.J. Medication-attributed adverse effects in placebo groups. Arch Intern Med 2006, 166:155-160.
13. Gatchel R.J., Peng Y.B., Peters M.L., et al. The biopsychosocial approach to chronic pain: Scientific advances and future directions. Psychol Bull 2007, 133:581-624.
14. Leeuw M., Goosens M.E.J.B., Linton S.J., et al. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med 2007, 30:77-94.
15. Chou R., Shekelle P. Will this patient develop persistent disabling low back pain?. JAMA 2010, 303:1295-1302.
16. Winters W., Devriese S., van Diest I., et al. Media warnings about environmental pollution facilitate the acqusition of symptoms in response to chemical substances. Psychosom Med 2003, 65:332-338.
17. Petrie K.J., Broadbent E.A., Kley N., et al. Worries about modernity predict symptom complaints after environmental pesticide spraying. Psychosom Med 2005, 67:778-782.
18. Stovner L.J., Oftedal G., Straume A., Johnsson A. Nocebo as headache trigger: evidence from a sham-controlled provocation study with RF fields. Acta Neurol Scand 2008, 188(suppl):67-71.
19. Mortazavi S.M., Ahmadi J., Shariati M. Prevalence of subjective poor health symptoms associated with exposure to electromagnetic fields among university students. Bioelectromagn 2007, 28:326-330.
20. Horne R., Weinman J., Hankins M. The beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999, 14:1-24.
21. Nestoriuc Y., Orav E.J., Liang M.H., et al. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res 2010, 62:791-799.
22. Kouyanou K., Pither C.E., Wessely S. Iatrogenic factors and chronic pain. Psychosom Med 1997, 59:597-604.
23. Meissner K., Bingel U., Colloca L., et al. The placebo effect: advances from different methodological approaches. J Neurosci 2011, 31:16117-16124.
24. Wells R., Kaptchuk T.J. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth 2012, 12:22-29.
25. Petrie K.J., Müller J.T., Schirmbeck F., et al. Effect of providing information about normal test results on patients' reassurance: randomised controlled trial. BMJ 2007, 334:352-355.
26. Brewin T.B. Three ways of giving bad news. Lancet 1991, 337:1207-1209.
27. Häuser W., Hansen E., Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Deusches Ärzteblatt 2012, 109:459-465.
28. Houben R.M., Ostelo R.W., Vlaeyen J.W.S., et al. Health care providers' orientations towards common low back pain predict perceived harmfulness of physical activities and recommendations regarding return to normal activity. Eur J Pain 2005, 9:173-183.
29. Darlow B., Fullen B.M., Dean S., et al. The association between health care professional attitudes and beliefs and the attitudes, beliefs, clinical management, and outcomes of patients with low back pain: a systematic review. Eur J Pain 2012, 16:3-17.
30. Buitenhuis J., de Jong P.J. Fear avoidance and illness beliefs in post-traumatic neck pain. Spine 2011, 36:S238-S243.
31. Linton S.J., Vlaeyen J., Ostelo R. The back pain beliefs of health-care providers: are we fear-avoidant?. J Occup Rehabil 2002, 12:223-232.
32. Lamont E.B., Christiakis N.A. Complexities in prognostication in advanced cancer: "To help them live their lives the way they want to". JAMA 2003, 290:98-104.
33. Ptacek J.T., Eberhardt T.L. Breaking bad news: a review of the literature. JAMA 1996, 276:496-502.
34. Buckman R. How to Break Bad News - a Guide for Health Care Professionals 1992, John Hopkins University Press, Baltimore.
35. Benedetti F., Amanzio M. The placebo response: how words and rituals change the patient's brain. Patient Educ Couns 2011, 84:413-419.
36. Benedetti F., Lanotte M., Lopiano L., Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neurosci 2007, 147:260-271.
37. Olshansky B. Placebo and nocebo in cardiovascular health: implications for healthcare, research, and the doctor-patient relationship. J Am Coll Cardiol 2007, 49:415-421.
38. Ong L.M.L., De Haes J.C.J.M., Hoos A.M., Lammes F.B. Doctor-patient communication: a review of the literature. Soc Sci Med 1995, 40:903-918.
39. WHO (World Health Organization) Adherence to Long-Term Therapies. Evidence for Action 2003, WHO, Geneva.
40. McCarberg B.H., Barkin R.L. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Amer J Ther 2001, 8:181-186.
41. Graziottin A., Gardner-Nix J., Stumpf M., Berliner M.N. Opioids: how to improve compliance and adherence. Pain Practice 2011, 11:574-581.
42. Kaptchuk T.J., Stason W.B., Davis R.B., et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006, 332:391-397.
43. Rief W., Nestoriuc Y., Weiss S., et al. Meta-analysis of the placebo response in antidepressant trials. J Affective Disord 2009, 118:1-8.
44. Papadopoulos D., Mitsikostas D. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 2010, 16:216-228.
45. Amanzio M., Corazzini L.L., Vase L., Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269.
46. Mondaini N., Gontero P., Giubilei G., et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. J Sex Med 2007, 4:1708-1712.
47. Myers M.G., Cairns J.A., Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther 1987, 42:250-253.
48. Miller F., Colloca L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. Theor Med Bioeth 2011, 32:229-243.
49. Barsky A.J., Goodson J.D., Lane R.S., Cleary P.D. The amplification of somatic symptoms. Psychosom Med 1988, 50:510-519.
50. Stern R.H. Nocebo responses to antihypertensive medications. J Clin Hypertens 2008, 10:723-725.
51. Berry D.C., Knapp P., Raynor D.K. Provision of information about drug side effects to patients. Lancet 2002, 359:853-854.
52. O'Connor A.M., Pennie R.A., Dales R.E. Framing effects on expectations, decisions, and side effects experienced: The case of influenza immunization. J Clin Epidemiol 1996, 49:1271-1276.
53. McNeil B.J., Pauker S.G., Sox H.J.J., Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 1982, 306:1259-1262.
54. Colloca L., Sigaudo M., Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008, 136:211-218.
55. Bingel U., Wanigasekera V., Wiech K., et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011, 3. 70ra14.
56. Benedetti F., Pollo A., Loopiano L., et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003, 23:4315-4323.
57. Dworkin S.F., Chen A.C., LeResche L., Clarke D.W. Cognitive reversal of expected nitrious oxide analgesia for acute pain. Anaesth Analg 1983, 62:1073-1077.
58. Svedman P., Ingvar M., Gordh T. 'Anxiebo,' placebo, and postoperative pain. BMC Anesthesiol 2005, 5:9.
59. Chae Y., Kim S.Y., Park H.S., et al. Experimentally manipulating perceptions regarding acupuncture elicits different responses to the identical acupuncture stimulation. Physiol Behav 2008, 95:515-520.
60. Benedetti F. How the doctor's words affect the patient's brain. Eval Health Prof 2002, 25:369-386.
61. Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004, 3:679-684.
62. Benedetti F., Carlino E., Pollo A. Hidden administration of drugs. Clin Pharm Ther 2011, 90:651-661.
63. Kelley J.M., Lembo A.J., Ablon J.S., et al. Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosom Med 2009, 71:789-797.
64. Varelmann D., Pancaro C., Cappiello E.C., Camann W.R. Nocebo-induced hyperalgesia during local anesthetic injection. Anesth Analg 2009, 110:868-870.
65. Sakala C. Letter from North America: understanding and minimizing nocebo effects in childbearing women. Birth 2007, 34:348-350.
66. Lang E.V., Hatsiopoulou O., Koch T., et al. Can words hurt? Patient-provider interactions during invasive procedures. Pain 2005, 114:303-309.
67. Zajonc R.B. Feeling and thinking: Preferences need no inferences. Am Psychol 1980, 35:151-157.
68. Taddio A., Shah V., Gilbert-MacLeod C., Katz J. Conditioning and hyperalgesia in newborns exposed to repeated heel lances. JAMA 2002, 288:857-861.
69. Colloca L., Petrovic P., Wager T.D., et al. How the number of learning trials affects placebo and nocebo responses. Pain 2010, 151:430-439.
70. Colloca L., Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcome. JAMA 2012, 307:567-568.
71. Miller F.G., Colloca L., Kaptchuk T.J. The placebo effect: illness and interpersonal healing. Perspect Biol Med 2009, 52:518-539.
72. Barrett B., Muller D., Rakel D., et al. Placebo, meaning and health. Perspect Biol Med 2006, 49:178-198.